A recent study published in JAMA Ophthalmology suggests that patients using semaglutide-based medications like Wegovy for weight loss and Ozempic, Rybelsus for type 2 diabetes may face an increased risk of nonarteritic anterior ischemic optic neuropathy (NAION). The study found higher incidence rates of NAION among those using semaglutide compared to non-GLP-1 medications, with significant risks noted particularly in diabetes and obesity treatments. Novo Nordisk acknowledged study limitations but emphasized the need for further investigation into these potential associations.